Effectiveness, Safety, and Tolerability of Bilastine Up-Dosing in Chronic Spontaneous Urticaria Uncontrolled with Licensed Doses of Other Second-Generation Antihistamines—An Institution-Based, Open-Label, Single-Group Longitudinal Trial
Background: Bilastine 20 mg daily is a second-generation antihistamine (sgAH) approved for chronic spontaneous urticaria (CSU). Up-dosing to 40 or 80 mg daily is recommended in uncontrolled patients. Aim and Objectives: Evaluating the effectiveness, safety, and tolerability of bilastine at 20, 40, a...
Enregistré dans:
| Auteurs principaux: | , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Wolters Kluwer Medknow Publications
2026-03-01
|
| Collection: | Indian Dermatology Online Journal |
| Sujets: | |
| Accès en ligne: | https://journals.lww.com/10.4103/idoj.idoj_7_25 |
| Tags: |
Pas de tags, Soyez le premier à ajouter un tag!
|